Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Rezafungin (Rezzayo) vs Vasopressin (Vasostrict)
An educational, source-based comparison of Rezafungin (Rezzayo) and Vasopressin (Vasostrict) — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly echinocandin for candidemia and invasive candidiasis.
Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.
- Candidemia
- Invasive candidiasis
- • FDA-approved (2023).
- • Infusion reactions and photosensitivity reported.
Endogenous nonapeptide that activates V1 vascular receptors to cause vasoconstriction and V2 renal receptors for water reabsorption. Used to raise blood pressure in catecholamine-resistant shock.
- Septic shock
- Cardiac arrest (historical)
- Diabetes insipidus
- • FDA-approved.
- • Ischemic complications possible at high doses.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Rezafungin (Rezzayo) | ReSTORE trial | Lancet | 2023 | Non-inferior to caspofungin for candidemia/invasive candidiasis. |
| Vasopressin (Vasostrict) | VASST trial | NEJM | 2008 | Vasopressin added to norepinephrine did not reduce mortality overall but benefited less severe septic shock. |
Side-effect & safety grid
- FDA-approved (2023).
- Infusion reactions and photosensitivity reported.
- FDA-approved.
- Ischemic complications possible at high doses.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Rezafungin (Rezzayo) vs Vasopressin (Vasostrict) — Key differences
- Class: Rezafungin (Rezzayo) is classified as Echinocandin · Antifungal, while Vasopressin (Vasostrict) is Vasopressor · Hormonal.
- Primary research focus: Rezafungin (Rezzayo) — candidemia; Vasopressin (Vasostrict) — septic shock.
- Tag: FDA-Approved · Antifungal vs FDA-Approved · Critical Care.